Loading
Life sciences · Journal article
Journal of Gastrointestinal Cancer · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The liver is involved in 30%-50% of patients with metastatic breast cancer and, when it becomes a dominant site of disease, portends survival inferior to bone- or soft-tissue-predominant metastasis. Systemic therapy—endocrine, HER2-directed, cytotoxic, and antibody-drug conjugates—remains the backbone of care for metastatic breast cancer. Most (> 95%) patients with breast cancer liver metastases (BCLM) harbor extrahepatic disease. Thus, the role of locoregional approaches for BCLM is limited. Moreover, given the heterogeneity of retrospective studies, selection bias, and lack of high level evidence, the survival benefit of locoregional therapies for BCLM remains inconclusive. On the other hand, locoregional therapy may be valuable for durable local control, symptom palliation, and, in highly selected oligometastatic patients, potentially prolonged disease-free intervals. This review surveys the four principal locoregional modalities for BCLM: surgical resection, ablation, transarterial therapies (chemoembolization and yttrium-90 radioembolization), and stereotactic body radiotherapy. Across all modalities the evidence is dominated by retrospective and case-matched series. Case-matched surgical cohorts report 5-year overall survival rates of 50–69% in rigorously selected patients, yet a controlled comparison found no survival advantage over medical therapy. Modality choice should be multidisciplinary and biology-informed, weighing molecular subtype, hepatic tumor burden, extrahepatic disease, and response to systemic therapy. Further prospective studies are needed to define the optimal role and sequencing of these interventions.